ReviewPathologie (Heidelberg, Germany)2026
[Diagnostic challenges in pediatric lymphomas].
Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphomas in children and adolescents account for only 1-2% of all lymphomas and differ markedly from adult cases in terms of subtype distribution, molecular profiles, and prognosis. This review summarizes current advances in the classification, biology, and diagnosis of pediatric lymphomas, with a focus on rare indolent entities and reactive, lymphoma-mimicking lesions.In addition to the more common entities such as Burkitt lymphoma, lymphoblastic lymphoma (particularly T‑lymphoblastic lymphoma), Hodgkin lymphoma, and ALK-positive anaplastic large cell lymphoma, children may present with rare indolent subtypes including pediatric type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (PNMZL), and testicular follicular lymphoma variants, all of which are associated with excellent prognosis. Aggressive subtypes comprise IRF4-rearranged large B‑cell lymphoma (LBCL-IRF4) and high-grade/large B‑cell lymphoma with 11q aberration (HG/LCBL-11q), both also demonstrating favorable outcomes. Particularly challenging in differential diagnosis are reactive lymphoid proliferations such as infectious mononucleosis, Kikuchi-Fujimoto disease, atypical marginal zone hyperplasia, and progressive transformation of germinal centers (PTGC).Pediatric lymphomas represent a heterogeneous group with specific clinical and biological features. Their diagnosis requires careful consideration to accurately distinguish rare indolent entities, recently defined large B‑cell lymphomas, and reactive mimics. Recent classifications, including the newly introduced WHO Classification of Pediatric Tumors, increasingly reflect these unique aspects.
Indexed as
Identifiers
41611915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.